Jupiter Topco LLC Buys Shares of 18,822,853 Boston Scientific Corporation $BSX

Jupiter Topco LLC bought a new position in Boston Scientific Corporation (NYSE:BSX) in the second quarter, Holdings Channel.com reports. The institutional investor bought 18,822,853 shares of the medical equipment provider’s stock, valued at approximately $803,357,000.

Other hedge funds have also modified their holdings of the company. ADAR1 Capital Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter worth approximately $320,000. Hsbc Holdings PLC raised its stake in shares of Boston Scientific by 3.9% during the 2nd quarter. Hsbc Holdings PLC now owns 3,533,722 shares of the medical equipment provider’s stock worth $150,598,000 after acquiring an additional 134,019 shares in the last quarter. EFG International AG purchased a new stake in Boston Scientific during the second quarter valued at approximately $59,000. Ancora Advisors LLC acquired a new stake in Boston Scientific in the second quarter valued at approximately $153,000. Finally, Primecap Management Co. CA acquired a new stake in Boston Scientific in the second quarter valued at approximately $2,156,233,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BSX shares. Royal Bank Of Canada reduced their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. Mizuho lowered their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Leerink Partners set a $60.00 target price on Boston Scientific in a research note on Thursday, July 30th. Oppenheimer cut their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 27th. Finally, Canaccord Genuity Group cut their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $71.62.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Up 1.7%

Boston Scientific stock opened at $49.86 on Wednesday. The business’s 50-day simple moving average is $46.44 and its two-hundred day simple moving average is $57.14. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market cap of $72.26 billion, a PE ratio of 20.19, a PEG ratio of 1.07 and a beta of 0.56. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the business posted $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has authorized a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.